ERAS
Price
$14.04
Change
-$0.45 (-3.11%)
Updated
Oct 22 closing price
Capitalization
4.91B
20 days until earnings call
Intraday BUY SELL Signals
SNGX
Price
$0.36
Change
-$0.00 (-0.00%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
7.91M
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs SNGX

ERAS vs SNGX Comparison Chart in %
View a ticker or compare two or three
VS
ERAS vs. SNGX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a StrongBuy and SNGX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ERAS with price predictions
Oct 22, 2026

ERAS's RSI Oscillator ascends from oversold territory

The RSI Indicator for ERAS moved out of oversold territory on September 24, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 31 of the 35 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where ERAS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on October 20, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 46 of 56 cases over the following month. The odds of a continued upward trend are 82%.

Following a +9.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 209 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ERAS as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ERAS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.570) is normal, around the industry mean (2.973). P/E Ratio (-14.779) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SNGX with price predictions
Oct 21, 2026

SNGX's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for SNGX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 48 similar instances when the indicator left oversold territory. In 41 of the 48 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 70 cases where SNGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on SNGX as a result. In 59 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for SNGX just turned positive on October 21, 2026. Looking at past instances where SNGX's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNGX advanced for three days, in 139 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

SNGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

SNGX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SNGX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.190) is normal, around the industry mean (2.988). P/E Ratio (-0.505) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. SNGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
SNGX: Fundamental Ratings
SNGX
OUTLOOK RATING
1..100
1
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
41
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASSNGX
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 2 days ago
70%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ERAS: $14.04 vs. SNGX: $0.36)
Brand notoriety: ERAS and SNGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 43% vs. SNGX: 33%
Market capitalization -- ERAS: $4.91B vs. SNGX: $7.93M
ERAS [@Biotechnology] is valued at $4.91B. SNGX’s [@Biotechnology] market capitalization is $7.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 2 FA rating(s) are green while SNGX’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 2 green, 3 red.
  • SNGX’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than SNGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while SNGX’s TA Score has 6 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 3 bearish.
  • SNGX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SNGX is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а -5.58% price change this week, while SNGX (@Biotechnology) price change was +6.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 11, 2026.

SNGX is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ERAS
Daily Signal:
Gain/Loss:
SNGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

SNGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNGX has been loosely correlated with ERAS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SNGX jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNGX
1D Price
Change %
SNGX100%
+2.48%
ERAS - SNGX
53%
Loosely correlated
-0.89%
CNTN - SNGX
46%
Loosely correlated
+11.56%
QURE - SNGX
36%
Loosely correlated
-0.11%
LGVN - SNGX
34%
Loosely correlated
-4.67%
DCOY - SNGX
32%
Poorly correlated
-5.73%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BCFN22.770.19
+0.84%
Baron Financials ETF (BCFN)
JPLD51.610.13
+0.25%
JPMorgan Limited Duration Bond ETF (JPLD)
VOXP40.26N/A
N/A
Vox Populi ETF (VOXP)
ENDW34.60-0.13
-0.36%
Cambria Endowment Style ETF (ENDW)
GVIP160.37-5.45
-3.29%
Goldman Sachs Hedge Industry VIP ETF (GVIP)